☆ 4.7 Meeting Abstract

Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 37, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2019.37.15_suppl.4581

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Urology & Nephrology

Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma

Andrea Necchi, Russell Madison, Sumanta K. Pal, Jeffrey S. Ross, Neeraj Agarwal, Guru Sonpavde, Monika Joshi, Ming Yin, Vincent A. Miller, Petros Grivas, Jon H. Chung, Siraj M. Ali

Summary: Differences in the genomic landscapes of UTUC and BUC were modest; however, patients with UTUC were enriched for FGFR3 and HRAS SV relative to BUC.

EUROPEAN UROLOGY FOCUS (2021)

Add to Collection

Review Oncology

Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice

Felix Lefort, Yasmine Rhanine, Mathieu Larroquette, Charlotte Domblides, Luc Heraudet, Baptiste Sionneau, Simon Lambert, Matthieu Lasserre, Gregoire Robert, Alain Ravaud, Marine Gross-Goupil

Summary: This review examines the differences and similarities between upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) in terms of their epidemiological, clinical, pathological, and biological features, and discusses the therapeutic consequences. The article discusses systemic treatments for invasive and metastatic diseases, and provides an overview of the expected developments in this field.

CANCERS (2023)

Add to Collection

Article Oncology

Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis

Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari

Summary: This study analyzed the clinicopathological features of FGFR3-mutated UTUC patients using public datasets and found that FGFR3 mutations may serve as a prognostic factor, and are more frequent in low-grade UTUCs with early-stage disease.

CLINICAL GENITOURINARY CANCER (2022)

Add to Collection

Review Genetics & Heredity

Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma

Elisa De Lorenzis, Giancarlo Albo, Fabrizio Longo, Carolina Bebi, Luca Boeri, Emanuele Montanari

Summary: Recent research on next-generation sequencing has characterized the genomic landscape of urothelial cancer, specifically focusing on the differences between upper urinary tract urothelial carcinomas (UTUC) and bladder cancer (BC). The study identified common genomic variations in UTUC, such as FGFR3, chromatin remodeling genes, TP53/MDM2, and discussed their potential implications for targeted therapy.

GENES (2021)

Add to Collection

Article Oncology

Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder

Kaiwei Yang, Wei Yu, Huanhuan Liu, Feng Ding, Yanrui Zhang, Yun Zhang, Wang Wang, Feng Lou, Shanbo Cao, Huina Wang, Zhisong He

Summary: The study revealed significant genomic differences and carcinogenesis prevalence between UTUC and UCB, with differences in mutational landscape and driver genes. This suggests the necessity for site-specific management of patients with urothelial carcinoma. Mutational signatures could serve as screening tools for clinical differential diagnosis between UTUC and UCB.

ONCOLOGIST (2021)

Add to Collection

Review Oncology

Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review

Masoud Bitaraf, Mahmood Ghafoori Yazdi, Erfan Amini

Summary: This study reviews the diagnostic tools and prognostic factors for patients with upper tract urothelial carcinoma (UTUC), and discusses the application of predictive tools in surgical decisions and postoperative treatment. It is recommended to revise the current classification of UTUC patients for more patients to benefit from kidney-sparing surgeries.

CANCERS (2023)

Add to Collection

Article Urology & Nephrology

Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma

Benjamin Pradere, David D'Andrea, Victor M. Schuettfort, Beat Foerster, Fahad Quhal, Keiichiro Mori, Mohammad Abufaraj, Vitaly Margulis, Marine Deuker, Alberto Briganti, Tim Muilwijk, Kees Hendricksen, Yair Lotan, Pierre Karakiewic, Shahrokh F.Shariat

Summary: The study assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy for UTUC. Low pre-therapy serum AGR was not found to be associated with pathological response or long-term oncological outcomes in this patient population.

WORLD JOURNAL OF UROLOGY (2021)

Add to Collection

Article Oncology

Regulatory region mutations of TERT, PLEKHS1 and GPR126 genes as urinary biomarkers in upper tract urothelial carcinomas

Xiangling Xing, Xiaotian Yuan, Tiantian Liu, Mingkai Dai, Yidong Fan, Cheng Liu, Klas Straat, Magnus Bjorkholm, Dawei Xu

Summary: The study found that hotspot mutations in the TERT, PLEKHS1, and GPR126 genes exist in UTUC tumors, different from UBCs. Detection of these mutated sequences in urine serves as potential biomarkers for UTUC diagnostics and disease monitoring.

JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics

Frederik Konig, Nico C. Grossmann, Francesco Soria, David D'Andrea, Tristan Juvet, Aaron Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Nozomi Hayakawa, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekaterina Laukhtina, Pawel Rajwa, Maximilian Pallauf, Giovanni E. Cacciamani, Thomas van Doeveren, Joost L. Boormans, Alessandro Antonelli, Marcus Jamil, Firas Abdollah, Jeffrey Budzyn, Guillaume Ploussard, Axel Heidenreich, Siamak Daneshmand, Stephen A. Boorjian, Morgan Roupret, Michael Rink, Shahrokh F. Shariat, Benjamin Pradere

Summary: Measuring the quality of care is important in improving patient outcomes. In this study, five indicators were identified to assess the quality of care for patients with upper urinary tract cancer who undergo surgical removal of the affected kidney and ureter. Patients who achieved all five indicators had higher chances of survival and lower rates of recurrence. There were no patient-related factors that predicted a failure to achieve these indicators.

CANCERS (2022)

Add to Collection

Article Urology & Nephrology

Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer

Kelly K. Bree, Patrick J. Hensley, Nathan A. Brooks, Justin Matulay, Roger Li, Graciela M. Nogueras Gonzalez, Neema Navai, Herbert Barton Grossman, Surena F. Matin, Colin P. N. Dinney, Ashish M. Kamat

Summary: Patients with UTUC prior to NMIBC diagnosis had higher rates of recurrence and progression after adequate BCG therapy, with high-grade UTUC-P associated with increased NMIBC recurrence.

BJU INTERNATIONAL (2021)

Add to Collection

Article Urology & Nephrology

Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?

Matthew Trail, Muhammad Sajid Waheed Rahman, William J. Broadhurst, James P. Blackmur, Abhishek Sharma, Etienne Chew, Marie O'Donnell, Julian Y. Keanie, John Brush, John Taylor, Simon Phipps, Ben Thomas, Edward A. A. Mains, S. Alan McNeill, Steve Leung, Mark L. Cutress, Alexander Laird

Summary: The aim of this study was to identify factors that may predict a diagnosis of upper urinary tract urothelial cell carcinoma (UTUC) and determine which patients can proceed directly to radical nephroureterectomy (RNU) without the delay of diagnostic ureteroscopy (URS). The study identified specific factors, such as visible haematuria, solid lesion on imaging, and a history of smoking, which may assist clinicians in selecting patients for RNU without the need for URS. These findings can be applied in a prospective multicentre analysis to further improve the selection process.

BJU INTERNATIONAL (2023)

Add to Collection

Article Medicine, General & Internal

Feasibility of Comprehensive Genomic Profiling (CGP) in Real-Life Clinical Practice

Lorenzo Nibid, Giovanna Sabarese, Daniela Righi, Silvia Maria Rossi, Giorgia Merlini, Pierfilippo Crucitti, Bruno Vincenzi, Giuseppe Tonini, Giuseppe Perrone

Summary: This study evaluated the CGP success rate in a cohort of 184 patients, and found that 81.5% of samples resulted in satisfying CGP reports. The CGP success rate was higher in samples from surgical specimens and in specimens stored for less than six months. However, the standard molecular testing strategy still provided clinically relevant molecular data in samples with inconclusive CGP reports. Therefore, the standard molecular testing strategy should not be replaced by CGP.

DIAGNOSTICS (2023)

Add to Collection

Review Medicine, General & Internal

Endoscopic Conservative Treatment of Upper Urinary Tract Urothelial Carcinoma with a Thulium Laser: A Systematic Review

Luigi Candela, Eugenio Ventimiglia, Catalina Solano, Marie Chicaud, Stessy Kutchukian, Frederic Panthier, Mariela Corrales, Luca Villa, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Steeve Doizi, Olivier Traxer

Summary: This article reviews the current evidence on the use of TLs for UTUC treatment. The results suggest that TL is a safe and effective endoscopic treatment for UTUC. However, there is a lack of prospective, multicentric studies with large population sizes and long-term follow-up in the available literature.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma

Petra Terezia Kovacs, Tamas Mayer, Anita Csizmarik, Melinda Varadi, Csilla Olah, Adam Szeles, Stephan Tschirdewahn, Ulrich Krafft, Boris Hadaschik, Peter Nyirady, Peter Riesz, Tibor Szarvas

Summary: This study investigated the serum levels of MMP-7 in UTUC patients and found that high pre-treatment serum MMP-7 concentrations were associated with shorter survival. This finding may improve preoperative risk assessment and therapeutic decision-making for UTUC.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Genomic profiling of Chinese patients with urothelial carcinoma

Bo Yang, Xiao Zhao, Chong Wan, Xin Ma, Shaoxi Niu, Aitao Guo, Jieli Wang, Jinliang Wang, Decong Sun, Shunchang Jiao

Summary: This study investigated the genomic features of Chinese urothelial carcinoma (UC) patients and found significant genetic alterations differences between UTUC and UCB. It also identified a reasonably good concordance of genomic features between circulating tumor DNA (ctDNA) and tissue samples.

BMC CANCER (2021)

Add to Collection

Article Oncology

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

A. V. Balar, D. E. Castellano, P. Grivas, D. J. Vaughn, T. Powles, J. Vuky, Y. Fradet, J. -L. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, A. Necchi, D. P. Petrylak, E. R. Plimack, J. Z. Xu, K. Imai, B. H. Moreno, J. Bellmunt, R. de Wit, P. H. O'Donnell

Summary: Immune checkpoint inhibitors are effective in treating metastatic urothelial carcinoma. Long-term follow-up is necessary to confirm the efficacy and safety of the treatment.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Oncology

The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit

Kristen McAlpine, Roderick Clark, Philippe E. Spiess, Andrea Necchi, Kenneth Gage, Robert J. Hamilton

Summary: Testicular cancer is a rare and often affects young and healthy patients. Imaging is crucial for the staging and surveillance of testicular cancer, as indeterminate findings can present challenges for clinicians and patients in treatment decisions.

CLINICAL GENITOURINARY CANCER (2023)

Add to Collection

Article Urology & Nephrology

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Juergen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begona P. Valderrama, Marc-Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, Keziban Unsal-Kacmaz

Summary: The CheckMate 274 trial demonstrated that adjuvant nivolumab improved disease-free survival (DFS) compared to placebo in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. The improvement in DFS was observed in patients with tumor programmed death ligand 1 (PD-L1) expression >= 1%.

EUROPEAN UROLOGY (2023)

Add to Collection

Article Oncology

Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy

Sean M. Hacking, Dean Pavlick, Yihong Wang, Benedito A. Carneiro, Matthew Mullally, Shaolei Lu, Mariana Canepa, Gennady Bratslavsky, Joseph Jacob, Andrea Necchi, Philippe E. Spiess, Li Wang, Evgeny Yakirevich, Jeffrey Ross

Summary: Comprehensive genomic profiling (CGP) was used to evaluate the frequency of NF2 genomic alterations in histologic subtypes of kidney tumors and co-occurring genomic alterations in other genes and biomarkers. The study found that NF2 mutations were more frequent in collecting duct carcinoma, sarcomatoid carcinoma, papillary carcinoma, and unclassified carcinoma, while less frequent in clear cell carcinoma, urothelial carcinoma of renal pelvis, and Wilms tumor. NF2-mutant RCC also exhibited co-occurring genetic alterations in CDKN2A/B, SETD2, and BAP1, which could potentially serve as therapeutic targets. Moreover, the higher level of PD-L1 expression in NF2-mutant tumors suggests that these tumors might be sensitive to immune checkpoint inhibitor therapies.

ONCOLOGIST (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

NEOADJUVANT PEMBROLIZUMAB SHOWS PROMISE AS EFFECTIVE SYSTEMIC THERAPY PRIOR TO RADICAL CYSTECTOMY

Kyle Rose, Marco Bandini, Heather Huelster, Giuseppe Basile, Shreyas Naidu, Philippe Spiess, Andrea Necchi, Roger Li

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

VENOUS TUMOUR THROMBUS IN RENAL CELL CARCINOMA: LOCALLY ADVANCED OR METASTATIC DISEASE?

Giacomo Musso, Giuseppe Basile, Alessandro Nini, Giuseppe Rosiello, Giuseppe Fallara, Chiara Re, Francesco Cei, Federico Belladelli, Daniele Cignoli, Roberta Luciano, Nazario Tenace, Isaline Rowe, Silvia Patricia Soares Pinto, Daniela Canibus, Andrea Necchi, Laura Marandino, Daniele Raggi, Roberto Bertini, Rayan Matloob, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Alessandro Larcher, Umberto Capitanio

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

BIOLOGY AND PERFORMANCE OF PRE- AND POST-PEMBROLIZUMAB (PEMBRO) VESICAL IMAGING-REPORTING AND DATA SYSTEM (VI-RADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): FULL DATA ANALYSIS FROM A CLINICAL TRIALS PIPELINE

Andrea Necchi, Giuseppe Basile, Ewan Gibb, Giuseppina Calareso, Tiago Padua, Damiano Patane, Emanuele Crupi, Chiara Mercinelli, Andrea Del Prete, Patrizia Giannatempo, Marco Moschini, Jeffrey Ross, Alberto Briganti, Francesco Montorsi, Antonella Messina, Francesco De Cobelli, Giorgio Brembilla

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

CHEMOTHERAPY VS IMMUNOTHERAPY AS NEOADJUVANT THERAPIES IN CISPLATIN-ELIGIBLE PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER

Luigi Nocera, Marco Bandini, Giuseppe Basile, Marco Moschini, Shreyas Naidu, Kyle Rose, Roger Li, Philippe Spiess, Andrea Necchi

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING - REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER

Giuseppe Basile, Giorgio Brambilla, Marco Bandini, Daniele Raggi, Laura Marandino, Tiago Costa De Padua, Emanuele Crupi, Renzo Colombo, Maurizio Colecchia, Roberta Luciano, Marco Moschini, Jeffrey S. Ross, Alberto Briganti, Francesco Montorsi, Francesco De Cobelli, Andrea Necchi

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

GENERALIZABILITY OF THE MK-6482-004 TRIAL TO REAL-WORLD VHL PATIENTS: RESULTS FROM A PROSPECTIVE SURVEILLANCE STUDY

Federico Belladelli, Chiara Re, Francesco Cei, Lucia Salerno, Sara Cusano, Floriana Iannace, Paola Carrera, Maria Grazia Patricelli, Andrea Falini, Francesco De Cobelli, Pietro Mortini, Francesco Bandello, Rosangela Lattanzio, Massimo Falconi, Stefano Partelli, Andrea Necchi, Daniele Raggi, Laura Marandino, Roberta Luciano, Isaline Rowe, Irene Franco, Francesco Montorsi, Umberto Capitanio, Alessandro Larcher, Andrea Salonia

JOURNAL OF UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303

A. Necchi, J. Bedke, M. D. Galsky, N. D. Shore, E. Xylinas, C. Jia, L. Dubrovsky, Moreno B. Homet, A. J. Witjes

EUROPEAN UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study

A. Necchi, T. Todenhoefer, J-L Deville, M. Hackl, M. Marszewska, P. Mckernan, M. Saulay, M. Engelhardt, M. De Santis

EUROPEAN UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

Exploring the effect of metastasis directed therapy on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer

A. Pellegrino, G. Gandaglia, A. Stabile, V. Cucchiara, E. Mazzone, A. Necchi, D. Raggi, L. Marandino, G. Rosiello, G. Sorce, F. Pellegrino, S. Scuderi, F. Barletta, D. Robesti, M. De Angelis, M. Longoni, P. Scilipoti, F. Montorsi, A. Briganti

EUROPEAN UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: Results from a prospective observational study

C. Re, F. Belladelli, F. Cei, L. Salerno, S. Cusano, F. Innace, G. B. Pipitone, P. Carrera, Russo A. Raucci, M. G. Patricelli, A. Falini, F. De Cobelli, P. Mortini, F. Bandello, R. Lattanzio, M. Falconi, S. Partelli, A. Necchi, L. Marandino, I Rowe, F. Montorsi, U. Capitanio, A. Larcher, A. Salonia

EUROPEAN UROLOGY (2023)

Add to Collection

Meeting Abstract Urology & Nephrology

The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211

D. Robesti, L. Nocera, F. Belladelli, J. G. Schultz, G. Fallara, L. Marandino, D. Raggi, F. Montorsi, A. Necchi, A. Martini

EUROPEAN UROLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.